Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum]

Clicks: 197
ID: 6322
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #1,581 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum] Rustomjee R, Zumla A. Delamanid expanded access novel treatment of drug resistant tuberculosis. Infection and Drug Resistance. 2015;8:359–366. Dr Rustomjee and Professor Zumla are grateful to a reader for raising some issues regarding referencing, and interpretation of their paper, and would like to clarify and address these issues. Read the original article 
Reference Key
roxana2016delamanidinfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Roxana Rustomjee;Alimuddin Zumla and
Journal Infection and drug resistance
Year 2016
DOI
10.2147/IDR.S101190
URL
Keywords
Infectious and parasitic diseases

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.